Phase II Alzheimer’s disease contract award

RNS Announcement

RNS Number : 2025Z

IXICO plc

20 May 2021

IXICO plc

("IXICO" or the "Company")

Phase II Alzheimer's disease contract award worth >£1m

IXICO plc (AIM:IXI), the AI data analytics company delivering insights in neuroscience, announces that it has been awarded an expansion contract by a current biopharmaceutical client to support the company's Phase II Alzheimer's disease clinical trial. Alzheimer's disease is a progressive degenerative disease affecting approximately 50 million people worldwide with devastating physical, emotional and financial impact to patients and families.

Conducted across 125 sites in 10 countries, the clinical trial will investigate efficacy, safety and tolerability of an anti-Tau antibody treatment for individuals with prodromal and mild Alzheimer's disease. For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), volumetric MRI (vMRI), diffusion MRI (dMRI) and arterial spin labelling (ASL).

The study is worth in excess of £1m over five years.

Lammert Albers, Chief Commercial Officer of IXICO, commented: "IXICO is delighted to be awarded the contract for this Alzheimer's disease clinical trial. With no available therapies to address the underlying disease pathology, Alzheimer's disease remains a critical area of unmet medical need, and we are proud to support sponsors in their tireless efforts to bring potential treatments for this devastating disease."

For further information please contact:

IXICO plc			+44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer

Cenkos Securities PLC (Nominated adviser and sole broker)				+44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales

Walbrook PR Ltd	+44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne /		[email protected]
Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTDKCBBABKDCPD

RNS metadata

Title: Phase II Alzheimer’s disease contract award
Time: 07:00:07
Date: 20 May 2021
Category: Acquisitions and alliances
ID: 2025Z